Close

Goldman Sachs Positive on Apellis Pharmaceuticals (APLS) Amid FDA Clarity

November 12, 2021 11:29 AM EST Send to a Friend
Goldman Sachs analyst Madhu Kumar reiterated a Buy rating and $100 price target on Apellis Pharmaceuticals (NASDAQ: APLS), saying the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login